• Publications
  • Influence
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
This trial assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity. Expand
Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.
The first comprehensive in vitro and in vivo investigations of the antitumor activity of the PARP inhibitor AG014699 in human cancer cells carrying mutated or epigenetically silenced BRCA1/2 were undertaken, indicating a potential role for PARP inhibitors in sporadic human cancers. Expand
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study
This study compared adult patients with cancer enrolled in the UK Coronavirus Cancer Monitoring Project between March 18 and May 8, 2020 with a parallel non-COVID-19 UK cancer control population, and analyzed the effect of primary tumour subtype, age, and sex and on severe acute respiratory syndrome coronavirus 2 prevalence and the case–fatality rate during hospital admission. Expand
A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors
Rucaparib was tolerable and had activity in patients with platinum-sensitive germline BRCA1/2–mutated HGOC, and the recommended phase II dose (RP2D) was selected based on manageable toxicity and clinical activity. Expand
Homologous recombination deficiency and ovarian cancer.
The expanded use of PARP inhibitors in HRD deficient (non-BRCA mutant) tumours using a signature of HRD in clinical practice requires validation. Expand
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian
This work investigated the efficacy and safety of single-agent rucaparib in germline (g) BRCA mutation carriers with advanced breast and ovarian cancers. Expand
Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
HR status can be determined in primary cancer samples by Rad51 focus formation, and this correlates with in vitro response to PARP inhibition, and use of this assay as a biomarker now needs testing in the setting of a clinical trial. Expand
Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?
The pre-clinical data supporting the use of ATR inhibitors as monotherapy and in combination with chemotherapy, radiotherapy and novel targeted agents such as PARP inhibitors are summarised. Expand
Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors
The pharmacokinetic profile of rucaparib was further evaluated at the recommended phase 2 dose of 600 mg BID (n = 26) and the mean (coefficient of variation) steady‐state maximum concentration (Cmax) and area under the concentration‐time curve from time zero to 12 hours (AUC0‐12h) were 1940 ng/mL and 16 900 ng ⋅ h/mL, respectively. Expand
The Potential of PARP Inhibitors in Genetic Breast and Ovarian Cancers
  • Y. Drew, H. Calvert
  • Biology, Medicine
  • Annals of the New York Academy of Sciences
  • 1 September 2008
This review summarizes the preclinical and clinical evidence for the potential of PARP inhibitors in genetic breast and ovarian cancers. Expand